Triglycerides,Medium Chain
Brain Hypoxia - Ischemia
Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Jens Rikardt Andersen
Modality
mixture
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Hypoxia - Ischemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Triglycerides,Medium Chain (this asset) | Jens Rikardt Andersen | N/A | D · 30 |
| Lacosamide | University of North Carolina, Chapel Hill | P4 | BB |
| Valproic Acid | University of North Carolina, Chapel Hill | P4 | BB |
| Fosphenytoin | University of North Carolina, Chapel Hill | P4 | B |
| Autologous Umbilical Cord Blood | Michael Cotten | P2 | CCC |
| Phenobarbital | University of North Carolina, Chapel Hill | P4 | CCC |
| Baclofen | University Hospital, Bordeaux | P2 | CCC |
| Methylphenidate | Massachusetts General Hospital | P1 | CC |
| Oxygen | Capital Medical University | N/A | D |
+2 more in the Brain Hypoxia - Ischemia cohort
Other indications for Triglycerides,Medium Chain
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastric Neoplasm | — | P4 | BB · 65 |
| Pancreatic Neoplasm | — | P4 | BB · 65 |
| Liver And Intrahepatic Bile Duct Neoplasm | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Triglycerides,Medium Chain in Brain Hypoxia - Ischemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/triglyceridesmedium-chain-brain-hypoxia-ischemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →